Pancreatic cancer

British Journal of Pharmacology

Volumn 171, Issue 4, 2014, Pages 849-858

  Gungor C ^a   Hofmann, B T ^a   Wolters Eisfeld, G ^a   Bockhorn, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

chemotherapy resistance; gemcitabine; midkine; Notch; pancreatic cancer; PDAC; therapy; tumour

Indexed keywords

FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; MIDKINE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH2 RECEPTOR; SONIC HEDGEHOG PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RECURRENCE; CELL ADHESION; CELL PROLIFERATION; DNA REPAIR; DRUG RESISTANCE; EARLY DIAGNOSIS; G1 PHASE CELL CYCLE CHECKPOINT; GENOME MAINTENANCE GENE; HUMAN; METASTASIS; MOLECULAR GENETICS; ONCOGENE; PANCREAS CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE; WNT SIGNALING PATHWAY;

CHEMOTHERAPY RESISTANCE; GEMCITABINE; MIDKINE; NOTCH; PANCREATIC CANCER; PDAC; THERAPY; TUMOUR;

ANIMALS; CYTOKINES; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84893068657     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12401     Document Type: Review

References (87)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M, (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
2. Assa-Kunik E, Torres IL, Schejter ED, Johnston DS, Shilo BZ, (2007). Drosophila follicle cells are patterned by multiple levels of Notch signaling and antagonism between the Notch and JAK/STAT pathways. Development 134: 1161-1169.
3. Barnes H, Larsen B, Tyers M, van Der Geer P, (2001). Tyrosine- phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC- transformed cells. J Biol Chem 276: 19119-19125.
4. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. (2007). Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738-744.
5. Burns JA, Issekutz TB, Yagita H, Issekutz AC, (2001). The alpha 4 beta 1 (very late antigen (VLA)-4, CD49d/CD29) and alpha 5 beta 1 (VLA-5, CD49e/CD29) integrins mediate beta 2 (CD11/CD18) integrin-independent neutrophil recruitment to endotoxin-induced lung inflammation. J Immunol 166: 4644-4649.
6. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
7. Caldas C, Kern SE, (1995). K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18: 1-6.
8. Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, et al. (2013). Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res 19: 549-559.
9. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, et al. (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122: 639-653.
10. Cooper CL, O'Toole SA, Kench JG, (2013). Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology 45: 286-304.
11. Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, et al. (2009). In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-Antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol 15: 1966-1972.
12. Dai L-C, (2009). Midkine translocated to nucleoli and involved in carcinogenesis. World J Gastroenterol 15: 412-416.
13. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. (2013). Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420.
14. Fabri L, Maruta H, Muramatsu H, Muramatsu T, Simpson RJ, Burgess AW, et al. (1993). Structural characterisation of native and recombinant forms of the neurotrophic cytokine MK. J Chromatogr 646: 213-225.
15. Fiorino S, Chili E, Bacchi-Reggiani L, Masetti M, Deleonardi G, Grondona AG, et al. (2013). Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-Analysis. Pancreatology 13: 147-160.
16. Güngör C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, et al. (2011). Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 71: 5009-5019.
17. Guo XZ, Cui ZM, Liu X, (2013). Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol 5: 20-28.
18. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
19. Halatsch ME, Hirsch-Ernst KI, Kahl GF, Weinel RJ, (1997). Increased expression of alpha6-integrin receptors and of mRNA encoding the putative 37 kDa laminin receptor precursor in pancreatic carcinoma. Cancer Lett 118: 7-11.
20. Heinemann V, Labianca R, Hinke A, Louvet C, (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-Agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18: 1652-1659.
21. Herreros-Villanueva M, Hijona E, Bañales JM, Cosme A, Bujanda L, (2013). Alcohol consumption on pancreatic diseases. World J Gastroenterol 19: 638-647.
22. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. (1990). Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422.
23. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
24. Huang Y, Hoque MO, Wu F, Trink B, Sidransky D, Ratovitski EA, (2008a). Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 7: 1613-1622.
25. Huang Y, Sook-Kim M, Ratovitski E, (2008b). Midkine promotes tetraspanin-integrin interaction and induces FAK-Stat1alpha pathway contributing to migration/invasiveness of human head and neck squamous cell carcinoma cells. Biochem Biophys Res Commun 377: 474-478.
26. Ikematsu S, Okamoto K, Yoshida Y, Oda M, Sugano-Nagano H, Ashida K, et al. (2003). High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun 306: 329-332.
27. Jiang P, Zang W, Wang L, Xu Y, Liu Y, Deng SX, (2013). Protein-protein interaction and SNP analysis in intraductal papillary mucinous neoplasm. Gene 513: 219-224.
28. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
29. Kadomatsu K, Huang RP, Suganuma T, Murata F, Muramatsu T, (1990). A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 110: 607-616.
30. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T, (1997). Midkine induces the transformation of NIH3T3 cells. Br J Cancer 75: 354-359.
31. Kadomatsu K, Kishida S, Tsubota S, (2013). The heparin-binding growth factor midkine: the biological activities and candidate receptors. J Biochem 153: 511-521.
32. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y, (2004). Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat Cell Biol 6: 547-554.
33. Kaname T, Kadomatsu K, Aridome K, Yamashita S, Sakamoto K, Ogawa M, et al. (1996). The expression of truncated MK in human tumors. Biochem Biophys Res Commun 219: 256-260.
34. Kishida S, Mu P, Miyakawa S, Fujiwara M, Abe T, Sakamoto K, et al. (2013). Midkine promotes neuroblastoma through Notch2 signaling. Cancer Res 73: 1318-1327.
35. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M, (2007). Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 35: 42-46.
36. Klein AP, (2013). Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13: 66-74.
37. Klimstra DS, (2007). Nonductal neoplasms of the pancreas. Mod Pathol 20: S94-S112.
38. Kopan R, (2012). Notch signaling. Cold Spring Harb Perspect Biol Oct 1; 4 (10). Review.
39. Kurtz A, Schulte AM, Wellstein A, (1995). Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog 6: 151-177.
40. Lerch MM, Mayerle J, (2013). 50 years of progress in pathophysiology, diagnosis and treatment of chronic pancreatitis. Z Gastroenterol 51: 358-362.
41. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, et al. (2011). Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
42. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, et al. (2012). KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21: 105-120.
43. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, et al. (2011). Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15: 817-828.
44. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et al. (1994). Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263: 89-92.
45. Lutz C, Nimpf J, Jenny M, Boecklinger K, Enzinger C, Utermann G, et al. (2002). Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP). J Biol Chem 277: 43143-43151.
46. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, et al. (2007). Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 97: 405-411.
47. Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA, (2013). Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 5: 26.
48. Matsui T, Ichihara-Tanaka K, Lan C, Muramatsu H, Kondou T, Hirose C, et al. (2010). Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds. Int Arch Med 21: 12.
49. McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME, (2012). Aberrant signalling pathways in pancreatic cancer: a two compartment view. Mol Carcinog 51: 25-39.
50. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. (2003). Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-576.
51. Miyashiro I, Kaname T, Shin E, Wakasugi E, Monden T, Takatsuka Y, et al. (1997). Midkine expression in human breast cancers: expression of truncated form. Breast Cancer Res Treat 43: 1-6.
52. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107: 246-251.
53. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al. (2009). Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15: 2291-2301.
54. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T, (2000). LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270: 936-941.
55. Muramatsu H, Zou P, Suzuki H, Oda Y, Chen GY, Sakaguchi N, et al. (2004). alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 117: 5405-5415.
56. Muramatsu T, (2002). Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. 132: 359-371.
57. Muramatsu T, (2010). Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 86: 410-425.
58. Muramatsu T, (2011). Midkine: a promising molecule for drug development to treat diseases of the central nervous system. Curr Pharm Des 17: 410-423.
59. Nobata S, Shinozawa T, Sakanishi A, (2005). Truncated midkine induces transformation of cultured cells and short latency of tumorigenesis in nude mice. Cancer Lett 219: 83-89.
60. O'Reilly EM, Abou-Alfa GK, (2007). Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34: 347-353.
61. Obata Y, Kikuchi S, Lin Y, Yagyu K, Muramatsu T, Kumai H, et al. (2005). Serum midkine concentrations and gastric cancer. Cancer Sci 96: 54-56.
62. Ohike N, Morohoshi T, (2011). Exocrine pancreatic neoplasms of nonductal origin: acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasm. Surg Pathol Clin 4: 579-588.
63. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, et al. (2013). Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol 71: 1231-1240.
64. Philip PA, (2008). Targeted therapies for pancreatic cancer. Gastrointest Cancer Res. 2 (4 Suppl. 2): S16-S19.
65. Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, Burrow CR, (1998). Midkine induces tumor cell proliferation and binds to a high affinity signalling receptor associated with JAK tyrosine kinases. J Biol Chem 273: 3654-3660.
66. Rose DM, Grabovsky V, Alon R, Ginsberg MH, (2001). The affinity of integrin alpha(4)beta(1) governs lymphocyte migration. J Immunol 167: 2824-2830.
67. Saif MW, (2007). Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 8: 545-552.
68. Sakamoto K, Bu G, Chen S, Takei Y, Hibi K, Kodera Y, et al. (2011). Premature ligand- receptor interaction during biosynthesis limits the production of growth factor midkine and its receptor LDL receptor-related protein 1. J Biol Chem 286: 8405-8413.
69. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130.
70. Sengbusch JK, He W, Pinco KA, Yang JT, (2002). Dual functions of [alpha]4[beta]1 integrin in epicardial development: initial migration and long-term attachment. J Cell Biol 157: 873-882.
71. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. (2002). Nuclear targeting by the growth factor midkine. Mol Cell Biol 22: 6788-6796.
72. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, et al. (2003). Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 94: 628-632.
73. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. (2012). Cancer treatment and survivorship statistics 2012. CA Cancer J Clin 62: 220-241.
74. Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Mätthai E, et al. (2013). LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol 6: 99-103.
75. Sounni NE, Noel A, (2013). Targeting the tumor microenvironment for cancer therapy. Clin Chem 59: 85-93.
76. Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, et al. (2013). Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res 73: 3902-3912.
77. Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, et al. (2013). Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20: 964-972.
78. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, et al. (2001). Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61: 8486-8491.
79. Takei Y, Kadomatsu K, Goto T, Muramatsu T, (2006). Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 107: 864-873.
80. Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K, et al. (2007). Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology 70: 1009-1013.
81. Tomomura M, Kadomatsu K, Matsubara S, Muramatsu T, (1990). A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J Biol Chem 265: 10765-10770.
82. Uehara K, Matsubara S, Kadomatsu K, Tsutsui J, Muramatsu T, (1992). Genomic structure of human midkine (MK), a retinoic acid-responsive growth/differentiation factor. J Biochem 111: 563-567.
83. Weinel RJ, Rosendahl A, Pinschmidt E, Kisker O, Simon B, Santoso S, (1995). The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 108: 523-532.
84. de Wilde RF, Ottenhof NA, Jansen M, Morsink FH, de Leng WW, Offerhaus GJ, et al. (2011). Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod Pathol 24: 1229-1236.
85. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS, (2008). 672 patients with acinar cell carcinoma of the pancreas: a population based comparison to pancreatic adenocarcinoma. Surgery 144: 141-148.
86. Yoong J, Michael M, Leong T, (2011). Targeted therapies for gastric cancer: current status. Drugs 71: 1367-1384.
87. Zhang N, Deuel TF, (1999). Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol 6: 44-50.